On Wednesday, Frontier Communications Corp (NASDAQ:FTR)’s shares inclined 4.30% to $4.85. The market capitalization of Frontier Communications Corp (NASDAQ:FTR) is $5.43 billion with the total traded volume of the company is 16.93 million. Turning to market valuation, , the Price-to-Sales ratio is 1.03 and the Price-to-Book ratio is finally 0.96. The dividend yield amounts to 8.66 percent and the beta ratio has a value of 0.75.
Frontier Communications Corporation, a communications company, provides regulated and unregulated voice, data, and video services to residential, business, and wholesale customers in the United States.
Nokia Corporation (ADR) (NYSE:NOK)’s shares dropped -1.04% to $7.14.
The initial offer period in Nokia’s public exchange offer (the “Offer”) for Alcatel-Lucent securities in both France and the United States has now closed. Accordingly, holders of Alcatel-Lucent shares, American Depositary Shares (“ADSs”) and OCEANEs may no longer tender into the Offer and may not withdraw Alcatel-Lucent shares, ADSs or OCEANEs that have already been tendered.
Nokia anticipates that the interim results of the initial public exchange offer will be published by the French stock market authority, Autorite des Marches Financiers (the “AMF”), on January 4, 2016, with the final results to be published on January 5, 2016. Assuming that the Offer is successful, it will be reopened. The AMF will publish the timetable of the reopened Offer, which is predictable to start on January 14, 2016 and close on February 3, 2016.
The completion of the Offer is subject to the voluntary minimum tender condition that the Alcatel-Lucent securities tendered into the Offer represent more than 50% of the shares of Alcatel-Lucent on a fully diluted basis upon the closing of the Offer. In accordance with the applicable rules and regulations of the AMF and the U.S. Securities and Exchange Commission, and if the mandatory minimum acceptance threshold set at more than 50% of the Alcatel-Lucent share capital or voting rights on a non-diluted basis (taking into account Alcatel-Lucent convertible bonds tendered into the exchange offer) is crossed, Nokia reserves the right to waive the voluntary minimum tender condition of the Offer. A decision regarding any waiver will be made by Nokia’s Board of Directors should that situation arise.
Nokia Corporation, together with its auxiliaries, provides network infrastructure and related services in Finland, the United States, Japan, China, India, the Russian Federation, Germany, Taiwan, Indonesia, Italy, and internationally.
Eli Lilly and Co (NYSE:LLY)‘s shares surged 0.34% to $86.20.
Halozyme Therapeutics, Inc. (HALO) declared a global partnershipand license agreement with Eli Lilly and Company (LLY) to develop and commercialize products combining proprietary Lilly compounds with Halozyme’s ENHANZE™ platform.
Under the terms of the agreement, Halozyme will receive an initial $25 million payment, followed by milestone payments of up to $160 million for each of up to five partnershiptargets valued at up to $800 million. These payments are subject to Lilly’s achievement of specified development, regulatory and sales-based milestones. In addition, Lilly will pay Halozyme mid-single digit royalties if products under the partnershipare commercialized.
The Halozyme ENHANZE platform is based on a proprietary recombinant human hyaluronidase enzyme (rHuPH20) that temporarily degrades hyaluronan — a chain of natural sugars in the body — to aid in the dispersion and absorption of other injected therapeutic drugs. For Lilly, this technology may allow for more rapid delivery of injectable medications through subcutaneous delivery.
“We are happy to collaborate with innovators like Halozyme as we develop our pipeline assets and optimize them for the clinic,” said Divakar Ramakrishnan, Ph.D., vice president of delivery and device research and development at Lilly. “Halozyme’s ENHANZE technology will provide a platform for our scientists to optimize delivery of Lilly medicines through subcutaneous injection.”
Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
